Literature DB >> 33135263

5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

J McCoy1, F A Cadegiani2, C G Wambier3, S Herrera4, S Vaño-Galván5, N A Mesinkovska6, P M Ramos7, J Shapiro8, R Sinclair9, A Tosti10, A Goren1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33135263     DOI： 10.1111/jdv.17021

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  21 in total

1.  Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial.

Authors:  Flavio A Cadegiani; Ricardo A Zimerman; Daniel N Fonseca; Michael N Correia; Marcio P Muller; Diego Leonardo Bet; Marcio Rafael Slaviero; Ivan Zardo; Paulo Roberto Benites; Renan N Barros; Raysa W Paulain; Dirce C Onety; Karla Cristina P Israel; Carlos Gustavo Wambier; Andy Goren
Journal:  Cureus       Date:  2021-12-25

Review 2.  Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis.

Authors:  Jean Kim; Kyle Miyazaki; Parthav Shah; Landon Kozai; Jakrin Kewcharoen
Journal:  Healthcare (Basel)       Date:  2022-03-30

3.  Do Anti-androgens Have Potential as Therapeutics for COVID-19?

Authors:  Franck Mauvais-Jarvis
Journal:  Endocrinology       Date:  2021-08-01       Impact factor: 4.736

4.  Extraordinary claims without extraordinary evidence: controversy on anti-androgen therapy for COVID-19.

Authors:  R M Trüeb; A Régnier; N Caballero-Uribe; M F Reis Gavazzoni Dias; H Dutra Rezende
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-04-08       Impact factor: 9.228

5.  Reply to comment on: The Gabrin sign.

Authors:  Carlos Gustavo Wambier; Sergio Vaño-Galván; Andy Goren
Journal:  J Am Acad Dermatol       Date:  2020-11-27       Impact factor: 11.527

6.  Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical).

Authors:  Flavio A Cadegiani; John McCoy; Carlos Gustavo Wambier; Andy Goren
Journal:  Cureus       Date:  2021-02-01

7.  Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial.

Authors:  Flavio A Cadegiani; John McCoy; Carlos Gustavo Wambier; Sergio Vaño-Galván; Jerry Shapiro; Antonella Tosti; Ricardo A Zimerman; Andy Goren
Journal:  Cureus       Date:  2021-02-22

Review 8.  Androgenetic alopecia and COVID-19: A review of the hypothetical role of androgens.

Authors:  Hamideh Moravvej; Mohammad Reza Pourani; Moein Baghani; Fahimeh Abdollahimajd
Journal:  Dermatol Ther       Date:  2021-06-09       Impact factor: 3.858

9.  Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.

Authors:  F A Cadegiani; A Goren; C G Wambier; J McCoy
Journal:  New Microbes New Infect       Date:  2021-07-07

10.  Workforce geography of older dermatologists during the COVID-19 pandemic.

Authors:  David X Zheng; Tarun K Jella; Melissa A Levoska; Anne Y Ning; Christopher R Cullison; Bryan T Carroll; Jeffrey F Scott
Journal:  Dermatol Ther       Date:  2021-03-06       Impact factor: 3.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.